top of page
  • The Review Course in Family Medicine

Transforming HIV Management With Long Acting Once Monthly Injectables

Someone cupping their ear showing that their hearing is poor. There is also a red colour effect around the ear showing there is a problem.

Long-acting anti-retroviral therapy is changing the landscape of HIV care. Increasing options promotes adherence leading to better patient outcomes.

Cabenuva is the injectable combined formulation of cabotegravir (Vocabria) + rilpivirine (Edurant), approved by Health Canada in 2020 to treat HIV-1. Individuals who tolerate to the oral formulations (Vocabria + Edurant) and have undetectable viral loads can be considered for Cabenuva, which is taken every 1-2 months.

Apretude is the injectable form of cabotegravir (Vocabria), the first and only injectable as pre-exposure prophylaxis (PrEP), Health Canada approval is expected in 2024. 

  • PrEP is almost 100% effective if taken consistently, but it’s often taken ‘as needed’ around sexual activity, which risks missed doses. Injectables promote adherence and HIV prevention.

Keep an eye out for this as long-acting PrEP is big step forward in HIV prevention!

Long-acting therapies like Cabenuva and Apretude are transforming HIV care, offering easier adherence and effective prevention. These injectables herald a new era in HIV treatment, promising a more manageable and hopeful future for those affected.




bottom of page